Thanks to the ONXX offer, biotech is on fire. Keep Junius and Perry out of the office and away from the phones, we don't need any more insider selling, or dilution. No news seems to be good news, keep them quiet. I am sure every biotech investment banker is calling their clients and trying to get them to do a secondary.
Someone on the IV board has been talking about EU updates, or potential for approval on the 25th. Other than Kadcyla approvals and sales numbers, the only thing I want to hear from IMGN execs is progress with the pipeline in HUMANS.
They are due to issue more options, glad they will be at $19+ and not $15. One year (last year I think), they announced an offering, tanked the price and then issued a large number of options to the execs at the lower price . That was highly unethical IMO and not to be repeated.